415 related articles for article (PubMed ID: 35037899)
1. Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects.
Chen X; Zhang W; Yang W; Zhou M; Liu F
Aging (Albany NY); 2022 Jan; 14(2):1048-1064. PubMed ID: 35037899
[TBL] [Abstract][Full Text] [Related]
2. Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment.
Dobosz P; Stępień M; Golke A; Dzieciątkowski T
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269988
[TBL] [Abstract][Full Text] [Related]
3. Dilemma and Challenge of Immunotherapy for Pancreatic Cancer.
Wu J; Cai J
Dig Dis Sci; 2021 Feb; 66(2):359-368. PubMed ID: 32140943
[TBL] [Abstract][Full Text] [Related]
4. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
5. Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer.
De Velasco MA; Kura Y; Fujita K; Uemura H
Int J Urol; 2024 Apr; 31(4):307-324. PubMed ID: 38167824
[TBL] [Abstract][Full Text] [Related]
6. Resistance to immune checkpoint inhibitors and the tumor microenvironment.
Kawashima S; Togashi Y
Exp Dermatol; 2023 Mar; 32(3):240-249. PubMed ID: 36437644
[TBL] [Abstract][Full Text] [Related]
7. Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies.
Zhou B; Gao Y; Zhang P; Chu Q
Front Immunol; 2021; 12():693609. PubMed ID: 34194441
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
[TBL] [Abstract][Full Text] [Related]
9. Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies.
Ajina R; Zahavi DJ; Zhang YW; Weiner LM
Semin Cancer Biol; 2020 Oct; 65():28-37. PubMed ID: 31866479
[TBL] [Abstract][Full Text] [Related]
10. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Wang Q; Xie B; Liu S; Shi Y; Tao Y; Xiao D; Wang W
Front Immunol; 2021; 12():773168. PubMed ID: 35003090
[TBL] [Abstract][Full Text] [Related]
11. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
12. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters.
Wang S; Xie K; Liu T
Front Immunol; 2021; 12():690112. PubMed ID: 34367148
[TBL] [Abstract][Full Text] [Related]
13. Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors.
Ahn R; Ursini-Siegel J
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807608
[TBL] [Abstract][Full Text] [Related]
14. TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy.
Qiu H; Shao Z; Wen X; Jiang J; Ma Q; Wang Y; Huang L; Ding X; Zhang L
Front Immunol; 2021; 12():716710. PubMed ID: 34539652
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of radiotherapy and targeted immunotherapy in improving tumor treatment efficacy: a review.
Dar TB; Biteghe FAN; Kakar-Bhanot R; Aniogo EC; Malindi Z; Akinrinmade OA; Chalomie NET; Kombe Kombe AJ; Aboughe Angone S; Ndong JMN; Ndong JD
Clin Transl Oncol; 2022 Dec; 24(12):2255-2271. PubMed ID: 35913663
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy-induced tumor physical microenvironment remodeling to overcome immunotherapy resistance.
Peng J; Yin X; Yun W; Meng X; Huang Z
Cancer Lett; 2023 Apr; 559():216108. PubMed ID: 36863506
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy and predictive immunologic profile: the tip of the iceberg.
Cunha Pereira T; Rodrigues-Santos P; Almeida JS; Rêgo Salgueiro F; Monteiro AR; Macedo F; Soares RF; Domingues I; Jacinto P; Sousa G
Med Oncol; 2021 Mar; 38(5):51. PubMed ID: 33788049
[TBL] [Abstract][Full Text] [Related]
18. Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets.
Ray SK; Mukherjee S
Curr Drug Targets; 2022; 23(5):471-485. PubMed ID: 35021970
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic Therapy and Immune Checkpoint Blockade
Cramer GM; Moon EK; Cengel KA; Busch TM
Photochem Photobiol; 2020 Sep; 96(5):954-961. PubMed ID: 32573787
[TBL] [Abstract][Full Text] [Related]
20. Dawn era for revisited cancer therapy by innate immune system and immune checkpoint inhibitors.
Kim HD; Yeh CY; Chang YC; Kim CH
Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167019. PubMed ID: 38211726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
